Piper Sandler Maintains Neutral on Fulgent Genetics, Raises Price Target to $19
Fulgent Genetics, Inc.
Fulgent Genetics, Inc. FLGT | 0.00 |
Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:
FLGT) with a Neutral and raises the price target from $15 to $19.
